Literature DB >> 22736085

Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions.

Paul Studenic1, Josef S Smolen, Daniel Aletaha.   

Abstract

BACKGROUND: The American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis (RA) have been published recently.
OBJECTIVE: To quantify the proportions of patients fulfilling only three of the four Boolean criteria and the relevance of patient global assessment (PGA) in context of remission.
METHODS: From an observational prospective RA database the first visit of patients, fulfilling just three of the four Boolean criteria was identified. Logistic regression and descriptive analyses were processed, also defining remission by index-based (Simplified Disease Activity Index (SDAI)) definition and comparing outcomes with the evaluator global assessment (EGA).
RESULTS: 52% had at least one visit, fulfilling just three criteria (not fulfilled were: PGA 61%; swollen joints 20%; tender joints 13%; C-reactive-protein 7%). 67% of patients not fulfilling the PGA criterion had an EGA≤1 cm, 25% of those fulfilled the SDAI definition. Increased pain (OR=1.28), EGA (OR=1.10) and discrepancy towards higher PGA than EGA (OR=1.28) could explain PGA failure to reach remission.
CONCLUSIONS: PGA is often the limiting factor for reaching remission; index-based remission showed balancing effects by adjusting for elevated variables in the summative score.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736085     DOI: 10.1136/annrheumdis-2012-201519

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients.

Authors:  Laure Gossec; John Richard Kirwan; Maarten de Wit; Andra Balanescu; Cecile Gaujoux-Viala; Francis Guillemin; Anne-Christine Rat; Alain Saraux; Bruno Fautrel; Tore K Kvien; Maxime Dougados
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

Review 2.  Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis.

Authors:  Maya H Buch; Stephen Eyre; Dennis McGonagle
Journal:  Nat Rev Rheumatol       Date:  2020-12-08       Impact factor: 20.543

3.  Predictors and the optimal duration of sustained remission in rheumatoid arthritis.

Authors:  Sibel Yilmaz-Oner; Ummugulsum Gazel; Meryem Can; Pamir Atagunduz; Haner Direskeneli; Nevsun Inanc
Journal:  Clin Rheumatol       Date:  2019-07-03       Impact factor: 2.980

4.  Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.

Authors:  Yvonne C Lee; Clifton O Bingham; Robert R Edwards; Wendy Marder; Kristine Phillips; Marcy B Bolster; Daniel J Clauw; Larry W Moreland; Bing Lu; Alyssa Wohlfahrt; Zhi Zhang; Tuhina Neogi
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02       Impact factor: 4.794

5.  What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of Life.

Authors:  Ethan T Craig; Jamie Perin; Scott Zeger; Jeffrey R Curtis; Vivian P Bykerk; Clifton O Bingham; Susan J Bartlett
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

6.  Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.

Authors:  Karel Pavelka; Zoltan Szekanecz; Nemanja Damjanov; Maria Majdan; Evgeny Nasonov; Vadim Mazurov; Tibor Fabo; Eustratios Bananis; Heather Jones; Annette Szumski; Boxiong Tang; Sameer Kotak; Andrew S Koenig; Radu Vasilescu
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

7.  Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria.

Authors:  Björn Svensson; Maria L E Andersson; Sidona-Valentina Bala; Kristina Forslind; Ingiäld Hafström
Journal:  BMJ Open       Date:  2013-09-10       Impact factor: 2.692

8.  Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.

Authors:  Shuji Asai; Nobunori Takahashi; Tomonori Kobayakawa; Atsushi Kaneko; Tatsuo Watanabe; Takefumi Kato; Tsuyoshi Nishiume; Hisato Ishikawa; Yutaka Yoshioka; Yasuhide Kanayama; Tsuyoshi Watanabe; Yuji Hirano; Masahiro Hanabayashi; Yuichiro Yabe; Yutaka Yokota; Mochihito Suzuki; Kenya Terabe; Naoki Ishiguro; Shiro Imagama; Toshihisa Kojima
Journal:  Clin Rheumatol       Date:  2021-06-16       Impact factor: 2.980

9.  Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis.

Authors:  Serena Bugatti; Ludovico De Stefano; Antonio Manzo; Garifallia Sakellariou; Blerina Xoxi; Carlomaurizio Montecucco
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-22       Impact factor: 5.346

10.  Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Authors:  Emese Balogh; Joao Madruga Dias; Carl Orr; Ronan Mullan; Len Harty; Oliver FitzGerald; Phil Gallagher; Miriam Molloy; Eileen O'Flynn; Alexia Kelly; Patricia Minnock; Madeline O'Neill; Louise Moore; Mairead Murray; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2013-12-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.